Mistral AI Acquires Emmi AI to Expand Industrial AI Solutions in Europe 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Asian Currencies Stay Rangebound as Dollar Holds Near Six-Week High Amid Iran War Concerns 
Japan Manufacturing Growth Slows in May as Services Sector Stagnates Amid Rising Middle East Supply Costs 
Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop 
China Delays Pentagon Official’s Beijing Visit Amid Taiwan Arms Deal Tensions 
Asian Stocks Rally as Nvidia Earnings Boost Tech Shares, Samsung Jumps on Wage Deal 
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships 
Rubio to Push NATO Defense Spending, Strengthen India Ties During Key Diplomatic Tour 
Asian Stocks Slide Ahead of Nvidia Earnings as Tech Shares Tumble 
ECB Signals Possible Rate Hike as Middle East Tensions Push Euro Zone Inflation Higher 
Samsung Union Confirms 18-Day Strike After Failed Wage Talks 
Iran-U.S. Talks Continue as Strait of Hormuz and Uranium Dispute Stall Peace Efforts 
Google Expands AI Partnership With Singapore Government 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
